Lubefaro et al
1
evaluated the efficacy of first-line carboplatin-paclitaxel (CP) or carboplatin-gemcitabine
(CG) combinations in 88 advanced triple-negative breast cancer (TNBC) patients. They
concluded that CG and CP are effective and well tolerated first-line platinum doublets
in advanced TNBC patients and CG could be more effective than CP in patients previous
exposed to taxanes despite worse toxicity profile. However, the time interval between
neoadjuvant treatment of a taxane regimen and development of metastatic disease was
not described. Current literature does not define the exact interval by which taxane
resistance is resolved. In the current study, a time interval pattern till time of
metastases for patients exposed to previous taxanes (within 1 year, between 1 and
2 years, or more than 2 years) might predict that some patients previously exposed
to taxanes might get more benefit from the taxane rechallenge.- Lobefaro R
- Mariani L
- Peverelli G
- et al.
Efficacy and safety of first-line carboplatin-paclitaxel and carboplatin-gemcitabine
in patients with advanced triple-negative breast cancer: a monocentric, retrospective
comparison.
Clin Breast Cancer. 2022; (S1526-8209(22)00286-5Epub ahead of print)https://doi.org/10.1016/j.clbc.2022.12.008
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Reference
- Efficacy and safety of first-line carboplatin-paclitaxel and carboplatin-gemcitabine in patients with advanced triple-negative breast cancer: a monocentric, retrospective comparison.Clin Breast Cancer. 2022; (S1526-8209(22)00286-5Epub ahead of print)https://doi.org/10.1016/j.clbc.2022.12.008
Article info
Publication history
Published online: January 25, 2023
Accepted:
January 22,
2023
Received:
January 15,
2023
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
